Metastatic melanoma: which BRAF/MEK inhibitor combination is best?

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • Indirect comparison of dabrafenib (Tafinlar) plus trametinib (Mekinist) with vemurafenib (Zelboraf) plus cobimetinib (Cotellic) suggests the 2 combinations have similar efficacy in metastatic melanoma, but adverse events are lower with dabrafenib plus trametinib.

Why this matters

 

 

  • These findings can help providers in the decision-making process when they are evaluating available options of BRAF/MEK inhibitor combinations for this population.

Study design

 

 

  • As there are no head-to-head studies, an indirect comparison was performed between dabrafenib plus trametinib and vemurafenib plus cobimetinib; 2 randomized trials were identified (dabrafenib plus trametinib vs vemurafenib with 704 patients and vemurafenib plus cobimetinib vs vemurafenib plus placebo with 495 patients).
  • Funding: Novartis.

Key results

 

 

  • The HR for OS and PFS and the overall response rate (ORR) for the 2 combinations was statistically nonsignificant.
  • For OS and PFS, the HR was 0.94 (P=.7227) and 1.05 (P=.730), respectively, and the ORR had a risk ratio (RR) of 0.90 (P=.3029).
  • Subgroup analyses showed no significant differences between the 2 combination therapies.
  • The incidence of any adverse event (RR, 0.92; P=.0015), any grade ≥3 adverse event (RR, 0.71; P=.0002), dose interruption/modification (RR, 0.77; P=.0471) were all significantly reduced with dabrafenib plus trametinib.

Limitations

 

 

  • Not a head-to-head trial.